Kimchi-Sarfaty Chava, Kasir Judith, Ambudkar Suresh V, Rahamimoff Hannah
Laboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.
J Biol Chem. 2002 Jan 25;277(4):2505-10. doi: 10.1074/jbc.M109154200. Epub 2001 Nov 7.
Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number ) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number ) Na(+)-Ca(2+) exchanger inhibited their transport activity in a concentration-dependent manner. The inhibition was detectable at 2 microm CsA, and exposure of the cells to 20 microm CsA resulted in a decrease of the Na(+)-dependent Ca(2+) uptake to about 20% relative to that of untreated cells. Determination of the surface expression of the exchanger protein revealed a parallel concentration-dependent reduction in the amount of the immunoreactive protein. No reduction was detected in the amount of total immunoreactive exchanger protein in CsA-treated cells relative to untreated ones. Among the different drugs tested, only PSC833, an analog of cyclosporin D, mimicked the effects of CsA. Exposure of the transfected cells to the chemically related cyclosporin D and macrolide drugs (FK506 or rapamycin) had no effect on the transport activity or the surface expression of the Na(+)-Ca(2+) exchanger. Co-expression of the human multidrug transporter P-glycoprotein (of which both drugs are modulators) with the cloned Na(+)-Ca(2+) exchanger revealed that transport activity and surface expression of each transporter in the co-transfected system were similar to those of each transporter alone in both the presence and absence of CsA or PSC833. CsA and PSC833 inhibited the surface expression of the NCX1 protein but did not alter the surface expression of P-glycoprotein. Unlike some P-glycoprotein endoplasmic reticulum-retained mutants (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem. 272, 709-712), CsA did not rescue RBE-2/F913-->Stop, an endoplasmic reticulum-retained function-competent mutant of the Na(+)-Ca(2+) exchanger (Kasir, J., Ren, X., Furman, I., and Rahamimoff, H. (1999) J. Biol. Chem. 274, 24873-24880) and did not induce its kinesis to the surface membrane, further demonstrating molecular differences between P-glycoprotein and NCX1 mutants for interaction with CsA.
用环孢菌素A(CsA)处理表达大鼠心脏RHE-1(NCX1.1,EMBL登录号 )或大鼠脑RBE-2(NCX1.5,GenBank(TM)登录号 )钠钙交换体的HEK 293细胞,可浓度依赖性地抑制其转运活性。在2 μM CsA时即可检测到抑制作用,将细胞暴露于20 μM CsA会导致钠依赖性钙摄取量相对于未处理细胞减少至约20%。对交换体蛋白的表面表达进行测定,结果显示免疫反应性蛋白量呈平行的浓度依赖性减少。与未处理细胞相比,CsA处理细胞中总的免疫反应性交换体蛋白量未检测到减少。在测试的不同药物中,只有环孢菌素D的类似物PSC833模拟了CsA的作用。将转染细胞暴露于化学相关的环孢菌素D和大环内酯类药物(FK506或雷帕霉素)对钠钙交换体的转运活性或表面表达没有影响。人多药转运体P-糖蛋白(这两种药物均为其调节剂)与克隆的钠钙交换体共表达表明,在存在和不存在CsA或PSC833的情况下,共转染系统中每种转运体的转运活性和表面表达与单独的每种转运体相似。CsA和PSC833抑制NCX1蛋白的表面表达,但不改变P-糖蛋白的表面表达。与一些内质网滞留的P-糖蛋白突变体不同(Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem. 272, 709 - 712),CsA不能挽救RBE-2/F913-->Stop,即钠钙交换体的一种内质网滞留但功能正常的突变体(Kasir, J., Ren, X., Furman, I., and Rahamimoff, H. (1999) J. Biol. Chem. 274, 24873 - 24880),也不能诱导其向表面膜移动,这进一步证明了P-糖蛋白与NCX1突变体在与CsA相互作用方面的分子差异。